vimarsana.com

Latest Breaking News On - James vane tempest - Page 6 : vimarsana.com

SCHOTT PHARMA : Jefferies sticks Neutral -January 31, 2024 at 02:15 am EST

In his latest research note, analyst James Vane-Tempest confirms his recommendation. The broker Jefferies is keeping its Neutral rating. The target price is being increased from EUR 30.40 to EUR.

James-vane-tempest
Markets

Sartorius at the top of the Dax after figures and outlook

Gute Quartalszahlen und eine zuversichtliche Prognose haben die Aktien von Sartorius am Freitag kräftig angetrieben. They gained more than 12 percent at times and were still up 9.5 percent at 330.70.

Abschreibungen-ebitda
Gute-quartalszahlen
Richard-vosser
Odysseas-manesiotis
Merck-kgaa
Merck-kga
Der-umsatz
James-vane-tempest
Markets

SARTORIUS VORZUEGE : Jefferies remains Neutral -January 26, 2024 at 04:40 am EST

Initially Neutral on the company, Jefferies s analyst James Vane-Tempest maintained his recommendation. The target price remains set at EUR 264.

Initially-neutral
James-vane-tempest
Markets

SCHOTT PHARMA : Jefferies gives a Neutral rating -January 26, 2024 at 06:15 am EST

In a research note published by James Vane-Tempest, Jefferies gives a Neutral rating to the stock. The target price is still set at EUR 30.40.

James-vane-tempest
Markets

Gerresheimer falls again - Jefferies lowers estimates

A multi-day recovery rally in Gerresheimer shares has come to an end at the exponential 200-day line. On Monday, the shares of the packaging specialist slipped again by almost 7 percent to 86.70.

Plastics-devices-division
James-vane-tempest
Markets

vimarsana © 2020. All Rights Reserved.